Geneva, Switzerland and Boston, MA – March 26, 2018– ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
Month: March 2018
Effects of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022 on Reproduction in Rats and Rabbits
Oliver Pohl, Roberta Sisti, Jean-Pierre Gotteland
SRI Conference, 06-10 March 2018, San Diego, CA
Abstract S-037: page 265A
Reproductive Sciences Vol. 25, Supplement 1, March 2018 265A Abstract S-037
Safety and Pharmacokinetics of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022: A First-in-Human Study in Healthy Women
Oliver Pohl, Ulrike Lorch, Line Marchand, Jean-Pierre Gotteland
SRI Conference, 06-10 March 2018, San Diego, CA
Abstract S-038: Pages 265A-266A
Reproductive Sciences Vol. 25, Supplement 1, March 2018 265A-266A Abstract S-038
ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update
Pipeline Achievements in 2017 Included Progress with Three Phase 3 and Two Phase 2 Clinical Trials Key 2018 Clinical Milestones…
Q4 2017 ObsEva SA Earnings Conference Call
ObsEva SA to Hold Fourth Quarter and Year-end 2017 Financial Results and Business Update Call on March 9, 2018
Geneva, Switzerland and Boston, MA – March 2, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development…
ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting
Oral administration of OBE022 shows favorable safety and results in predictable exposureNon-clinical results of OBE022 for PTL demonstrating fetal safety…